Stem Cell Transplantation for Hurler

This study has been completed.

Study NCT00176917 Information provided by Masonic Cancer Center, University of Minnesota

First Received on September 12, 2005. Last Updated on July 2, 2010 History of Changes

Results First Received: July 28, 2009

Study Type:	Interventional
Study Design:	Allocation: Non-Randomized; Endpoint Classification: Efficacy Study; Intervention Model: Single Group Assignment; Masking: Open Label; Primary Purpose: Treatment
Conditions:	Mucopolysaccharidosis I Mucopolysaccharidosis VI Mannosidosis Mucolipidosis Type II (I-cell Disease)
Interventions:	Procedure: Stem Cell Transplant Drug: Busulfan, Cyclophosphamide, ATG

Participant Flow

Hide Participant Flow

Recruitment Details

Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
No text entered.

Pre-Assignment Details

Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups

	Description
Transplant Patients	Patients that received hematopoietic stem cell transplant.

Participant Flow: Overall Study

	Transplant Patients
STARTED	41
COMPLETED	41
NOT COMPLETED	0

Baseline Characteristics

Hide Baseline Characteristics

Reporting Groups

	Description
Transplant Patients	Patients that received hematopoietic stem cell transplant.

Baseline Measures

	Transplant Patients
Number of Participants [units: participants]	41
Age [units: participants]
<=18 years	41
Between 18 and 65 years	0
>=65 years	0
Age [units: years] Mean ± Standard Deviation	1.8 ± 1.4
Gender [units: participants]
Female	23
Male	18
Region of Enrollment [units: participants]
United States	41

Outcome Measures

Show All Outcome Measures

1. Primary:

Mean Percentage of Donor Cells in Study Population (Chimerism). [ Time Frame: at 21 days, 42 days, 60 days, 100 days, 6 months, and 1 year ]

Show Outcome Measure 1

2. Secondary:

Number of Patients Surviving on Study [ Time Frame: at 100 days, 1 year, and 3 years post transplant ]

Show Outcome Measure 2

3. Secondary:

Number of Patients Who Failed Engraftment. [ Time Frame: Day 42 Post Transplant ]

Show Outcome Measure 3

4. Secondary:

Number of Patients With Grade III-IV Acute Graft-versus-host Disease (aGVHD). [ Time Frame: Day 100 Post Transplant ]

Show Outcome Measure 4

Serious Adverse Events

Show Serious Adverse Events

Other Adverse Events

Show Other Adverse Events

More Information

Hide More Information

Certain Agreements:

All Principal Investigators ARE employed by the organization sponsoring the study.

Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
Based on variability in age, diagnosis and condition of these patients, the data on enzyme levels and neuropsych testing is extremely difficult to report. See Secondary Outcome Measures #3 and #4; no other adverse events were collected.

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data

Based on variability in age, diagnosis and condition of these patients, the data on enzyme levels and neuropsych testing is extremely difficult to report.

See Secondary Outcome Measures #3 and #4; no other adverse events were collected.

Results Point of Contact:

Name/Title: Paul J. Orchard, M.D.
Organization: Masonic Cancer Center, University of Minnesota
phone: 612-626-2313
e-mail: orcha001@umn.edu

No publications provided

Responsible Party:	Orchard, Paul J., MD, Masonic Cancer Center at the University of Minnesota
ClinicalTrials.gov Identifier:	NCT00176917 History of Changes
Obsolete Identifiers:	NCT00005899
Other Study ID Numbers:	UMN-MT1999-07, 0104M93821
Study First Received:	September 12, 2005
Results First Received:	July 28, 2009
Last Updated:	July 2, 2010
Health Authority:	United States: Institutional Review Board